News & Blog

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Congressional Resolution Passes to Designate September 25 as “National Ataxia Awareness Day”

Papillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia

Stealth BioTherapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance and FARA Ireland to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich’s Ataxia

Meet the 2024 FARA Fellows

FA Community Conversations Genetic Therapies Webinar: Recording Available on YouTube

FARA Celebrates 16 Years of Funding Adaptive Cycling Equipment Through The Ataxian Athlete Initiative (AAI) 

United Against Ataxia Hill Day 2024 – Registration open!

August 2024 – Advocacy Newsletter

Join us for FA Community Conversations – Genetic Medicine on August 29, 2024

Larimar Therapeutics Reports Several Updates on Nomlabofusp FA Program in Q2 2024 Operating and Financial Results

Job Opening – Accounting Specialist